Drug companies defend discount programs in the wake of GAO scrutiny

Washington, D.C.-Drug manufacturers are revamping their recentlyannounced discount programs in order to gainsay a recent survey from theU.S. General Accounting Office, which reported that the discount card programsmight not have the impact and savings that they had intended.